Members Only Content
Subscribe to get full access
Free Preview
Right now, the genetic medicine developer boasts four clinical-stage assets. It expects that to grow to six by the end of 2021 and to at least 10 by the end of 2022.
Upstart Recommendation Report Upstart Presentation Slides
Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]
PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]
